The fixed-effects meta-analysis in SSc combined group was suggestive for lower serum adiponectin levels in SSc patients than healthy controls (SMD (95% CI) = −0.16 (−0.35 to 0.02)), albeit not statistically significant (p = 0.07). This evidence concerns the gene ADIPOQ and systemic sclerosis.